ストックスクリーナーアプリを入手
0.405
20.82%
0.0698
アフターアワーズ：
.45
0.045
+11.11%
前日終値:
$0.3352
開ける：
$0.3542
24時間の取引高:
14.39M
Relative Volume:
13.85
時価総額：
$19.47M
収益：
-
当期純損益:
$-22.83M
株価収益率:
-0.5127
EPS:
-0.79
ネットキャッシュフロー:
$-20.87M
1週間 パフォーマンス:
+24.81%
1か月 パフォーマンス:
+30.69%
6か月 パフォーマンス:
-46.36%
1年 パフォーマンス:
-77.12%
1日の値動き範囲:
$0.3528
$0.4177
1週間の範囲:
$0.2933
$0.4177
52週間の値動き範囲:
$0.2223
$2.535
Cognition Therapeutics Inc Stock (CGTX) Company Profile
名前
Cognition Therapeutics Inc
セクター
電話
412-481-2210
住所
2403 SIDNEY STREET, PITTSBURGH
CGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.405 | 19.47M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 開始されました | B. Riley Securities | Buy |
| 2021-11-03 | 開始されました | Oppenheimer | Outperform |
Cognition Therapeutics Inc (CGTX) 最新ニュース
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus
Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks
Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq
Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire
Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan
B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World
HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World
Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan
CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times
zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive
Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log
Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com
Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus
COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph
Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader
Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com
Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
Cognition Therapeutics Inc (CGTX) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):